[HTML][HTML] Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab
American journal of transplantation, 2010 - Elsevier
The applicability of islet transplantation as treatment for type 1 diabetes is limited by renal
and islet toxicities of currently available immunosuppressants. We describe a novel …
and islet toxicities of currently available immunosuppressants. We describe a novel …
Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.
AM Posselt, MD Bellin, M Tavakol, GL Szot… - American Journal of …, 2010 - europepmc.org
The applicability of islet transplantation as treatment for type 1 diabetes is limited by renal
and islet toxicities of currently available immunosuppressants. We describe a novel …
and islet toxicities of currently available immunosuppressants. We describe a novel …
Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab
AM Posselt, MD Bellin, M Tavakol… - … : official journal of …, 2010 - pubmed.ncbi.nlm.nih.gov
The applicability of islet transplantation as treatment for type 1 diabetes is limited by renal
and islet toxicities of currently available immunosuppressants. We describe a novel …
and islet toxicities of currently available immunosuppressants. We describe a novel …
Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti‐LFA‐1 Antibody Efalizumab
AM Posselt, MD Bellin, M Tavakol, GL Szot… - American Journal of …, 2010 - infona.pl
The applicability of islet transplantation as treatment for type 1 diabetes is limited by renal
and islet toxicities of currently available immunosuppressants. We describe a novel …
and islet toxicities of currently available immunosuppressants. We describe a novel …
Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab
AM Posselt, MD Bellin, M Tavakol, GL Szot… - American Journal of …, 2010 - experts.umn.edu
The applicability of islet transplantation as treatment for type 1 diabetes is limited by renal
and islet toxicities of currently available immunosuppressants. We describe a novel …
and islet toxicities of currently available immunosuppressants. We describe a novel …
[引用][C] Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti-LFA-1 Antibody Efalizumab
AM Posselt, MD Bellin, M Tavakol, GL Szot… - American Journal of …, 2010 - cir.nii.ac.jp
Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the
Anti-LFA-1 Antibody Efalizumab | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
Anti-LFA-1 Antibody Efalizumab | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …
[HTML][HTML] Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti-LFA-1 Antibody Efalizumab
AM Posselt, MD Bellin, M Tavakol, GL Szot… - American Journal of …, 2010 - amjtransplant.org
The applicability of islet transplantation as treatment for type 1 diabetes is limited by renal
and islet toxicities of currently available immunosuppressants. We describe a novel …
and islet toxicities of currently available immunosuppressants. We describe a novel …
[HTML][HTML] ISLET TRANSPLANTATION IN TYPE 1 DIABETICS USING AN IMMUNOSUPPRESSIVE PROTOCOL BASED ON THE ANTI-LFA-1 ANTIBODY EFALIZUMAB
AM Posselt, MD Bellin, M Tavakol, GL Szot… - American journal of …, 2010 - ncbi.nlm.nih.gov
The applicability of islet transplantation as treatment for type 1 diabetes is limited by renal
and islet toxicities of currently available immunosuppressants. We describe a novel …
and islet toxicities of currently available immunosuppressants. We describe a novel …
Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti‐LFA‐1 Antibody Efalizumab
AM Posselt, MD Bellin, M Tavakol… - American Journal of …, 2010 - Wiley Online Library
The applicability of islet transplantation as treatment for type 1 diabetes is limited by renal
and islet toxicities of currently available immunosuppressants. We describe a novel …
and islet toxicities of currently available immunosuppressants. We describe a novel …
[引用][C] Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on the Anti-LFA-1 Antibody Efalizumab
AM POSSELT, MD BELLIN… - American journal of …, 2010 - pascal-francis.inist.fr
Islet Transplantation in Type 1 Diabetics Using an Immunosuppressive Protocol Based on
the Anti-LFA-1 Antibody Efalizumab CNRS Inist Pascal-Francis CNRS Pascal and Francis …
the Anti-LFA-1 Antibody Efalizumab CNRS Inist Pascal-Francis CNRS Pascal and Francis …